MeCHOta® CHO-K1 cell line is derived from ECACC CHO-K1, adapted to suspension culture in serum-free medium and selected by monoclonal screening, It has global authorization and proven supporting service kit(expression vector, medium), ensuring stable production capacity from laboratory to commercial scale.
MeCHOta® CHO-K1 is derived from CHO-K1 (ECACC 85051005), with clear background and clear lineage, meeting the compli- ance requirements of excellent commercial engineering cell lines.
Stability, compliance (traceability) and scalability (excellent metabolism) are the most important indicators for evaluating commer- cial engineering cell lines. MeCHOta® CHO-K1 has a clear background, complete traceability and compliance, has passed compre- hensive cell testing, has reliable stability, excellent metabolic level and environmental tolerance, meets all standards of engineering cell lines, and is an excellent commercial project cell line.
Originated from ECACC CHO K1, complete purchase records, customs declaration list, temperature control records and cell COA.
Expression vectors with independent intellectual property rights and customized matching culture media.
Genetic stability across passages, consistent productivity and product quality, stable transgene integration and copy number.
Performed in CD CHO 031 basal medium using serum-free, chemically defined medium throughout the process.
Sterility, mycoplasma, endogenous viral factors, retrovirus, cell identification, etc.
Maintains low lactate levels and tolerates high ammonium and hyperosmotic conditions.
MeCHOta® CHO-K1 has uniform cell shape and size (~15μm), stable growth, short doubling time (~20h), and excellent growth characteristics. It is an ideal cell line for commercial large-scale production.
The MCB and WCB established by MeCHOta® CHO-K1 under cGMP conditions have been tested for cell identification, sterility, mycoplasma,endogenous and adventitious viruses, and retroviruses, ensuring production compliance and safety under the GMP system.
MeCHOta® CHO-K1 has a proven supporting services kit, including the expression vector system (pTOB series) with indepen- dent intellectual property rights, and the corresponding high-expression medium, to help customers quickly advance projects from DNA sequences to shelf products.
MeCHOta® CHO-K1 exhibits excellent stability in multiple dimensions such as copy number of exogenous genes, cDNA sequence, passaging, expression level, and expression quality, and no sequence variants are produced, meeting the requirements of commercial continuous production.
|
Molecule Code (based on amino acid sequence) |
Molecule Type | Cell Line |
|---|---|---|
| A | mAb-IgG1 | MeCHOta® CHO-K1 |
| B | mAb-IgG1 | MeCHOta® CHO-K1 |
| C | mAb-IgG1 | MeCHOta® CHO-K1 |
| D | mAb-IgG1 | MeCHOta® CHO-K1 |
| E | BsAb-IgG1 | MeCHOta® CHO-K1 |
| F | mAb-IgG1 | MeCHOta® CHO-K1 |
| G | mAb-IgG4 | MeCHOta® CHO-K1 |
| H | mAb-IgG4 | MeCHOta® CHO-K1 |
| I | IgE-A | MeCHOta® CHO-K1 |
| J | mAb-IgG1 | MeCHOta® CHO-K1 |
| K | mAb-IgG1 | MeCHOta® CHO-K1 |
Note: MeCHOta® CHO-K1 is derived from ECACC CHO-K1.
Our MeCHOta® CHO-K1 host cells demonstrate high-yield production, achieving high titers ranging across 11 molecules - including 9 monoclonal antibodies, 1 bispecific antibody (8.1 g/L), and 1 IgE-λ molecule.
| Molecule | Qp | SEC | nrCE-SDS | rCE-SDS | |||||
|---|---|---|---|---|---|---|---|---|---|
| Molecule | type | (pg/cell/d) | HMW | Main | LMW | LMW | Main | HMW | LC+HC |
| (%) | (%) | (%) | (%) | (%) | (%) | (%) | |||
| C | mAb-IgG1 | 52 | 1.8 | 98.1 | 0.0 | 5.7 | 94.3 | / | 98.9 |
| D | mAb-IgG1 | 56 | 0.0 | 99.3 | 0.7 | 4.0 | 96.0 | / | 99.0 |
| G | mAb-IgG4 | 44 | 3.7 | 96.1 | 0.2 | 4.3 | 95.7 | / | 98.1 |
| H | mAb-IgG4 | 68 | 3.9 | 93.5 | 2.5 | 3.9 | 96.1 | / | / |
| E | mAb-IgG1 | 32 | 1.3 | 98.5 | 0.2 | 6.1 | 93.9 | / | 98.1 |
| Molecule | Molecule | N-Glycan (%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| type | G0-GN | G0F-GN | G0 | G0F | Man5 | G1Fa | G1Fb | G2F | G2S1F | G2S2F | Others | |
| C | mAb-IgG1 | 1.5 | 3.5 | 6.4 | 54.5 | 4.8 | 16.5 | 6.1 | 2.0 | / | / | 4.7 |
| D | mAb-IgG1 | 1.9 | 2.9 | 6.9 | 40.8 | 6.0 | 23.7 | 6.8 | 4.1 | / | / | 6.9 |
| G | mAb-IgG4 | 0.5 | 1.1 | 3.9 | 71.6 | 1.3 | 8.0 | 7.9 | 2.1 | / | / | 3.6 |
| H | mAb-IgG4 | 1.7 | 3.5 | 6.4 | 48.3 | 5.1 | 11.5 | 11.2 | 3.9 | / | / | 8.4 |
| E | mAb-IgG1 | 0.3 | 0.6 | 3.5 | 51.9 | 0.8 | 19.9 | 8.7 | 6.5 | 1.8 | 1.5 | 4.5 |
MeCHOta® CHO-K1 exhibits excellent stability in multiple dimensions such as copy number of exogenous genes, cDNA sequence, passaging, expression level, and expression quality, and no sequence variants are produced, meeting the requirements of commercial continuous production.
Confirm partnership with TOBio, with plans to utilize the CHO-K1 cell line.
TOBio files the cell usage record with ECACC.
You sign an agreement with TOBio to define the scope of rights.
You obtain the cell line and sub-license to proceed with commercialization legally.
(Note: ECACC = European Collection of Authenticated Cell Cultures, a recognized world-leading cell bank)
Worldwide commercialization rights.
No annual fees, royalties, or hidden costs.
Existing sub-licenses are unaffected by future agreement changes.
